OmniSeq - About the company
OmniSeq is a series B company based in Buffalo (United States), founded in 2015 by Carl Morrison. It operates as a Labcorp Oncology: Advancing cancer care through diagnostics, research, and precision medicine. OmniSeq has raised $8.89M in funding from Hitachi High-Tech Corporation. The company has 405 active competitors, including 134 funded and 82 that have exited. Its top competitors include companies like MedGenome, Geneoscopy and Caris Life Sciences.
Company Details
Labcorp Oncology: Advancing cancer care through diagnostics, research, and precision medicine. They are dedicated to improving patient outcomes through comprehensive genomic and immune profiling for solid tumors. Their services extend to contract research, including genomic and immune profiling, gene expression analysis, and sequencing. They offer diagnostic reference and specialty labs, supporting healthcare, pharma, and medtech industries. They focus on precision medicine, cell and gene therapies, and digital pathology, leveraging scientific lab disciplines like genetics and toxicology. They provide resources for patients and biopharma partners, including education, events, and scientific expertise. They offer online portals for test results, order adjustments, and specimen tracking, ensuring seamless access and management. They are committed to advancing healthcare access, scientific research, and sustainable business practices.
- Website
- omniseq.com
- Social
- Registered Address
- 700 ELLICOTT STREET, BUFFALO, United States, 14203, NY
Key Metrics
Founded Year
2015
Location
Buffalo, United States
Stage
Series B
Total Funding
$8.89M in 5 rounds
Latest Funding Round
Investors
Ranked
105th among 405 active competitors
Employee Count
25 as on Jul 31, 2026
Legal entities associated with OmniSeq
OmniSeq is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
OMNISEQ, INC. CIN: 001t000000Wo9lmAAB , United States, Active | Aug 01, 2017 | - | - | - |
Sign up to download OmniSeq's company profile
OmniSeq's funding and investors
OmniSeq has raised a total funding of $8.89M over 5 rounds. Its first funding round was on Aug 18, 2017. OmniSeq has 3 institutional investors.
Here is the list of recent funding rounds of OmniSeq:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jun 20, 2019 | 7498789 | Series B | 7611268 | 8599650 | 5298674 | 1808758 |
May 02, 2019 | 4394943 | Series B | 7527917 | 5467892 | 9361760 | 5202210 |
Apr 12, 2018 | 3008933 | Series B | 4030461 | 3749622 | 5659399 |
Access funding benchmarks and valuations. Sign up today!View details of OmniSeq's funding rounds and investors
OmniSeq's founders and board of directors
Founder? Claim ProfileThe founders of OmniSeq is Carl Morrison.
Here are the details of OmniSeq's key team members:
- Carl Morrison: Founder of OmniSeq.
View details of OmniSeq's Founder profiles and Board Members
OmniSeq's employee count trend
OmniSeq has 25 employees as of Jul 26. Here is OmniSeq's employee count trend over the years:
Uncover OmniSeq's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
OmniSeq's Competitors and alternates
Top competitors of OmniSeq include MedGenome, Geneoscopy and Caris Life Sciences. Here is the list of Top 10 competitors of OmniSeq, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Provider of DNA sequencing, bioinformatics, and multiomics services | $264M | 70/100 | ||
2nd | Geneoscopy 2015, St. Louis (United States), Series C | Developer of non-invasive biomarker tests for colorectal cancer | $219M | 67/100 | |
3rd | Caris Life Sciences 1996, Irving (United States), Public | Developer of panomic disease profiling technologies for cancer precision medicine | $1.23B | 66/100 | |
4th | Intellia Therapeutics 2014, Cambridge (United States), Public | Developer of therapeutics based on CRISPR/Cas9 technology for multiple diseases | $85M | 66/100 | |
5th |  Noetik 2022, San Francisco (United States), Series A | Developer of AI-driven platform for cancer immunotherapy discovery and development | $62M | 62/100 | |
6th |  Deep Genomics 2014, Toronto (Canada), Series C | AI-powered platform for RNA biology to accelerate genetic therapy discovery | $238M | 62/100 | |
7th |  UniQure 1998, Amsterdam (Netherlands), Public | Developer of gene-based therapies for patients with genetic or acquired diseases | $111M | 62/100 | |
8th |  Waypoint 2021, New York City (United States), Series A | Digital cell therapy platform for providers | $34.5M | 61/100 | |
9th | GenSight Biologics 2011, Paris (France), Public | Developer of viral vector-based gene therapies for retinal neurodegenerative diseases | $76.6M | 61/100 | |
10th |  Seres Therapeutics 2010, Cambridge (United States), Public | Developer of microbiome therapeutics to treat a wide range of diseases | $134M | 60/100 | |
105th | OmniSeq 2015, Buffalo (United States), Series B | Labcorp Oncology: Advancing cancer care through diagnostics, research, and precision medicine | $8.89M | 41/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on OmniSeq's competitors? Click here to see the top ones
OmniSeq's Investments and acquisitions
OmniSeq has made no investments or acquisitions yet.
Reports related to OmniSeq
Here is the latest report on OmniSeq's sector:
News related to OmniSeq
Filter this list•
Labcorp And OmniSeq Launch INSIGHT, Next-Generation Sequencing Platform to Advance Precision OncologyAiThority•Jun 14, 2021•LabCorp, OmniSeq
•
OmniSeq Receives New York State Approval for Cancer Genomic, Immune Profiling TestGenomeWeb•Apr 27, 2021•OmniSeq
•
OmniSeq, UPMC Partner on Immunotherapy Trial Matching for Head and Neck CancerGenomeWeb•Jan 28, 2021•UPMC, OmniSeq
•
•
OmniSeq Appoints Chief Medical Officer, Roger D. Klein, M.D., J.D., FCAPCMOCRO•Apr 07, 2020•OmniSeq, Hunt Scanlon, Slone Partners
•
OmniSeq Board Names Margot Schoenborn to Succeed Mark Gardner as CEOGlobeNewswire•Jun 26, 2019•OmniSeq
•
OmniSeq and LabCorp Extend Exclusive Distribution Pact and Complete Follow-On Investment AgreementCMOCRO•Apr 23, 2019•OmniSeq, LabCorp
•
•
OmniSeq Receives CAP Accreditation and Publishes Analytical Validation PaperCMOCRO•Nov 09, 2017•OmniSeq
•
Omniseq And LabCorp (LH) Sign Exclusive Distribution Agreement And Series B Funding CommitmentBioSpace•Aug 21, 2017•OmniSeq, LabCorp
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about OmniSeq
Explore our recently published companies
- CL MediCall Aid - United Kingdom based, 2009 founded, Unfunded company
- Genera - San Isidro based, Unfunded company
- Gladwin Area - United States based, Unfunded company
- Lindab Ireland - Ireland based, 1959 founded, Unfunded company
- Pinecrest Construction and - United States based, 1991 founded, Unfunded company
- Jaguar Asheville - Fletcher based, Unfunded company
